Further, the interaction observed between GIVVDR rs2881514 and GIV25(OH)D demonstrates evidence for interaction between increased VDR binding at rs2881514 and decreased 25(OH)D serum levels, yielding a substantial increase in the risk of MS (Meta-analysis OR: 2.17, 95% CI: 1.10–4.29). This evidence concerns the gene VDR and myeloid sarcoma.